Changeflow GovPing Healthcare FinCEN Healthcare Fraud Advisory - 24 Red Flags...
Routine Notice Added Final

FinCEN Healthcare Fraud Advisory - 24 Red Flags and Enhanced Reporting

Favicon for www.jdsupra.com JD Supra Healthcare
Published March 30th, 2026
Detected April 7th, 2026
Email

Summary

FinCEN issued an advisory on March 30, 2026, urging financial institutions to be vigilant in identifying and reporting suspicious transactions related to healthcare fraud schemes targeting Medicare, Medicaid, and other federal and state health care benefit programs. The advisory applies broadly to banks, broker-dealers, investment companies, insurance companies, and certain real estate businesses, providing 24 red flag indicators for identifying fraud and money laundering activity. Financial institutions are encouraged to voluntarily report suspicious activity and notify law enforcement regarding fraud schemes targeting Health Care Benefit Programs.

What changed

FinCEN's advisory provides financial institutions with an overview of common healthcare fraud schemes, including use of straw owners and shell companies, false claims for non-existent or unnecessary medical care, and obfuscation of fraudulent reimbursements through U.S. and international financial systems. The advisory highlights 24 red flag indicators such as customers with prior healthcare fraud convictions, transfers to recently established shell companies, and sudden significant increases in reimbursements.\n\nFinancial institutions should expect enhanced expectations on their AML programs and may need to conduct deeper due diligence on healthcare company ownership and transactions. Healthcare providers opening new accounts may face increased scrutiny regarding ownership and business model. Both financial institutions and healthcare companies should review compliance policies to meet these enhanced expectations and prepare for potential new whistleblower program requirements aimed at institutions that fail to detect and report fraud.

What to do next

  1. Monitor for updates on FinCEN whistleblower program rulemaking
  2. Review and modify AML compliance policies to address healthcare fraud red flags
  3. Implement enhanced due diligence for healthcare company accounts and ownership structures

Source document (simplified)

April 7, 2026

FinCEN Issues Advisory to Financial Sector Enhancing Obligations with Respect to Policing Health Care Fraud Schemes

LinkedIn Facebook X Send Embed

On March 30, 2026, as part of the Trump Administration’s commitment to rooting out fraud against the government, the United States Department of the Treasury’s Financial Crimes Enforcement Network (“FinCEN”) issued an advisory “to urge financial institutions to be vigilant in identifying and reporting suspicious transactions potentially related to health care fraud schemes targeting Medicare, Medicaid, and other Federal and state health care benefit programs.” This advisory applies to a broad range of those in the financial sector including banks, broker dealers, investment companies, insurance companies, certain real estate businesses, and more. FinCEN also proposed new rulemaking for its whistleblower program, which appears to be aimed at financial institutions who do not adequately detect and report fraud. While this advisory appears aimed at combatting overt healthcare fraud, it will likely have an impact on a wide variety of healthcare and financial services businesses who are not involved in such fraud. In response, financial institutions and healthcare companies should consider reviewing and modifying their compliance policies and procedures to meet these enhanced expectations.

Highlights of the FinCEN Advisory:

  • The FinCEN advisory provides financial institutions with an overview of common health care fraud schemes targeting Health Care Benefit Programs, including:
    • The use of straw owners and shell companies;
    • The filing of false and fraudulent claims for non-existent, exploitative, substandard, or unnecessary medical care; and
    • The obfuscation of fraudulent reimbursements through the U.S. and international financial systems.
  • The advisory also highlights associated money laundering concerns and lists 24 red flag indicators to identify and report suspicious activity to FinCEN.
    • Some examples of red flags include:
    • Customers opening accounts for health care businesses when the customer, or their beneficial owners, have prior health care fraud or government benefits fraud convictions;
    • Customers starting accounts for health care businesses when their owners are not legal permanent residents of the United States or have no significant prior experience in the healthcare industry;
    • Transfers of a significant amount of reimbursements to recently established shell companies;
    • A health care provider receives significant reimbursements soon after opening or soon after a change in beneficial ownership; and
    • Any sudden significant increase in reimbursements.
  • FinCEN reiterates financial institutions’ reporting requirements under the Bank Secrecy Act (“BSA”).
  • FinCEN strongly encourages financial institutions to voluntarily report suspicious activity related to fraud.
  • Finally, FinCEN strongly encourages immediate notification to law enforcement regarding fraud schemes targeting Health Care Benefit Programs.
    Impacts on Financial Institutions and Healthcare Providers:

  • The advisory appears to place enhanced expectations on financial services companies associated with their anti-money laundering (“AML”) programs and monitoring of healthcare fraud specifically. Companies may be obligated to dig much deeper into the ownership and transactions of healthcare companies than they previously thought.

  • This could also increase the burden on new healthcare providers setting up financial accounts as financial institutions may be asking questions about their ownership and business model that they have never asked before.

  • There is an increased chance of healthcare companies having their accounts closed, or being “derisked”, by banks and others for unusual business models.

  • This will also likely increase the diligence cost on transactions in the healthcare and financial services spaces, including in financial technology.

  • There is an increased risk of governmental investigations into healthcare companies, and potentially into financial institutions for failure to properly detect and report suspicious activity (regardless of whether the underlying allegations have merit).

  • There will also likely be increased costs associated with subpoenas and other investigative matters for both financial services companies and healthcare companies.

  • Finally, the proposed whistleblower program will increase the volume of whistleblower reports against financial services clients and healthcare clients. This means that employers will need to encourage internal reporting and investigation. Employers may also need to be more cautious about how they handle terminations and other employment actions lest they be accused of retaliation.
    Send Print Report

    Latest Posts

  • FinCEN Issues Advisory to Financial Sector Enhancing Obligations with Respect to Policing Health Care Fraud Schemes

  • 2026 Alabama Legislative Update: Regular Session - Week Eleven

  • Taking The Pulse, A Health Care and Life Sciences Video Podcast | Episode 271: Advancing Neurotrauma Treatments with Ken Webb of NeuroHope Therapeutics Video

  • Alabama’s Revised Office‑Based Surgery Rules: What Physicians and Physician Offices Need to Know

  • Elevating Healthcare Oversight: FTC Unveils Task Force to Address Market Consolidation and Innovation
    See more »

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.
Attorney Advertising.

©
Maynard Nexsen
2026

Written by:

Maynard Nexsen Contact + Follow David Kinman + Follow Matthew Roberts + Follow Erica Williamson Barnes + Follow

PUBLISH YOUR CONTENT ON JD SUPRA

  • ✔ Increased readership
  • ✔ Actionable analytics
  • ✔ Ongoing writing guidance Join more than 70,000 authors publishing their insights on JD Supra

Start Publishing »

Published In:

Anti-Money Laundering + Follow Bank Secrecy Act + Follow Financial Institutions + Follow Financial Services Industry + Follow FinCEN + Follow Healthcare Fraud + Follow Medicaid + Follow Medicare + Follow Reporting Requirements + Follow Risk Management + Follow Criminal + Follow Finance & Banking + Follow Health + Follow Insurance + Follow more

Maynard Nexsen on:

Solve with 2Captcha

Solve with 2Captcha

Named provisions

Bank Secrecy Act reporting requirements Voluntary suspicious activity reporting Law enforcement notification

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
Maynard Nexsen
Published
March 30th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Banks Insurers Healthcare providers
Industry sector
5221 Commercial Banking 5241 Insurance 6211 Healthcare Providers
Activity scope
Suspicious activity reporting AML program compliance Healthcare fraud monitoring
Geographic scope
United States US

Taxonomy

Primary area
Anti-Money Laundering
Operational domain
Compliance
Compliance frameworks
BSA/AML
Topics
Healthcare Banking Financial Services

Get Healthcare alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when JD Supra Healthcare publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.